Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 3(3)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07457190Phase 1Not Yet Recruiting

Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

Role: lead

NCT07457203Phase 1Not Yet Recruiting

Study on the Drug Interaction Between Buagafuran and Voriconazole

Role: lead

NCT06243640Phase 3Recruiting

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Role: lead

NCT06243614Phase 3Recruiting

Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Role: lead

NCT05063500Phase 3Unknown

The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI

Role: collaborator

NCT02944552Phase 2Completed

The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Role: collaborator

All 6 trials loaded